as 02-13-2025 9:54am EST
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
Founded: | 2010 | Country: | United States |
Employees: | N/A | City: | ISELIN |
Market Cap: | 56.3M | IPO Year: | 2016 |
Target Price: | $21.00 | AVG Volume (30 days): | 807.8K |
Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -4.06 | EPS Growth: | N/A |
52 Week Low/High: | $0.87 - $12.85 | Next Earning Date: | 02-25-2025 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | 396.84% |
OTLK Breaking Stock News: Dive into OTLK Ticker-Specific Updates for Smart Investing
GlobeNewswire
9 days ago
GlobeNewswire
13 days ago
GlobeNewswire
21 days ago
GlobeNewswire
22 days ago
MT Newswires
a month ago
MT Newswires
a month ago
Benzinga
a month ago
GlobeNewswire
a month ago
The information presented on this page, "OTLK Outlook Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.